Novo executives were keen to speak on Wegovy’s growing success during the company’s earnings call Wednesday, with David Moore, the drugmaker’s head of U.S. operations and global business ...

In this video, I will go over Novo Nordisk's (NVO-3.62%) and Eli Lilly's recent earnings report. Watch the short video to learn more, consider subscribing, and click the special offer link below.

Investing.com -- Novo Nordisk 's (CSE:NOVOb) stock jumped over 3% on Wednesday following a stronger-than-expected fourth-quarter profit, boosted by an increase in sales of Wegovy, the company's ...

Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other ...

Novo Banco was created in 2014 as a result of a government bailout of collapsed Banco Espirito Santo. U.S. fund Lone Star owns a 75% stake, with Portugal's resolution fund and the state holding ...

Investing.com -- Novo Nordisk 's (CSE:NOVOb) stock jumped over 3% on Wednesday following a stronger-than-expected fourth-quarter profit, boosted by an increase in sales of Wegovy, the company's weight ...

LISBON, Jan 31 (Reuters) - U.S. private equity firm Lone Star has told the Portuguese government that it is likely to sell a 25-30% stake in Novo Banco via an initial public offering, rather than ...

(Reuters) -The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with ...

Novo Nordisk, meanwhile, faced a 5% share price decline on Friday after outgoing U.S. president Joe Biden announced the company’s semaglutide drug, the medication used in Wegovy and Ozempic ...

registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.

Novo Nordisk (NVO) announced Friday that its popular obesity therapy, semaglutide, marketed as Wegovy, led to 20.7% weight loss over 72 weeks at a higher dose of 7.2 mg in a late-stage trial ...

The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The FDA ...